Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial
2011

Effects of Sevelamer Carbonate on Heart Health in Kidney Disease

Sample size: 120 publication 10 minutes Evidence: moderate

Author Information

Author(s): Chue Colin D, Townend Jonathan N, Steeds Richard P, Ferro Charles J

Primary Institution: University Hospitals Birmingham NHS Foundation Trust

Hypothesis

Phosphate binding with sevelamer carbonate will reduce left ventricular mass, improve indices of left ventricular systolic and diastolic function, and reduce arterial and cardiac stiffness in patients with stage 3 CKD.

Conclusion

The study aims to determine if sevelamer carbonate can improve heart function and reduce stiffness in patients with chronic kidney disease.

Supporting Evidence

  • Serum phosphate is linked to heart problems in kidney disease.
  • Sevelamer carbonate is a non-calcium phosphate binder.
  • Previous studies suggest sevelamer may help reduce heart risks.

Takeaway

This study is trying to find out if a medicine called sevelamer can help people's hearts work better when they have kidney problems.

Methodology

A single-centre, prospective, randomised, double-blind, placebo-controlled trial with 120 subjects receiving either sevelamer carbonate or placebo over 40 weeks.

Potential Biases

Potential bias in participant selection and reporting of outcomes due to the single-centre design.

Limitations

The study is limited to a single centre and may not be generalizable to all populations.

Participant Demographics

Adults aged 18-80 years with stage 3 chronic kidney disease.

Statistical Information

P-Value

<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1745-6215-12-30

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication